Close Menu

NEW YORK – NeoGenomics announced Thursday the pricing of its proposed offerings of shares of common stock and convertible senior notes.

The company is offering 4.4 million shares of its common stock at $28.50 per share, with expected gross proceeds of $125.4 million, and $175 million of its 1.25 percent convertible senior notes due in 2025. The senior notes will mature on May 1, 2025. 

NeoGenomics also granted the underwriters of the offerings a 30-day option to buy an additional 666,000 shares of common stock at the public offering price and $26.25 million of senior notes.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.